---
id: 245
title: Enterococcus Species
category: organisms
subcategory: gram_positive_cocci
tags: [Enterococcus, VRE, ampicillin, vancomycin-resistant, UTI, endocarditis]
difficulty: high
---

## Question

What are key clinical syndromes and treatment considerations for *Enterococcus*? Use **"Ampicillin (If Susceptible), Vancomycin (VRE Common), Synergy for Endocarditis (Add Gentamicin)"** framework.

## Answer

### **Species:**

***E. faecalis*** (80-90%)
- **More common, less resistant**
- **Usually ampicillin-susceptible**

***E. faecium*** (10-20%)
- **More resistant** (often VRE, ampicillin-resistant)
- **Healthcare-associated**

### **Key Clinical Syndromes:**

**Urinary Tract Infections:**
- **Most common enterococcal infection** (catheter-associated, elderly)
- **Often polymicrobial**

**Intra-Abdominal/Pelvic Infections:**
- **Part of polymicrobial flora** (uncertain pathogenic role)
- **Treat if:** Septic, immunocompromised, persistent symptoms

**Bacteremia:**
- **Often from GU or GI source**
- **Central line-associated**
- **High mortality if endocarditis**

**Endocarditis:**
- **Subacute, indolent**
- **Often older men, GU instrumentation**
- **Requires synergistic therapy** (ampicillin + gentamicin)

**Wound/Soft Tissue:**
- **Diabetic foot ulcers, pressure ulcers** (polymicrobial)

### **Antimicrobial Resistance:**

**Intrinsic Resistance:**
- **Cephalosporins** (all generations) - do NOT cover *Enterococcus*
- **Aminoglycosides** (monotherapy) - low-level resistance
- **TMP-SMX, clindamycin, aztreonam**

**Acquired Resistance:**

**Vancomycin-Resistant *Enterococcus* (VRE):**
- **VanA** (high-level resistance to vancomycin + teicoplanin) - most common, transmissible
- **VanB** (variable vancomycin resistance, teicoplanin-susceptible)
- **Risk factors:** Prolonged hospitalization, ICU, antibiotics (especially vancomycin, cephalosporins), immunosuppression

**Ampicillin-Resistant:**
- ***E. faecium*** - often ampicillin-resistant (intrinsic)
- **β-lactamase rare** (but can occur)

**High-Level Aminoglycoside Resistance (HLAR):**
- **Loss of synergy** (cannot use aminoglycoside with cell-wall agent for endocarditis)

### **Treatment:**

**UTI:**

***E. faecalis* (Ampicillin-Susceptible):**
- **Ampicillin 500mg PO QID × 7 days** (uncomplicated)
- **Amoxicillin 500mg PO TID × 7 days**
- **Nitrofurantoin 100mg PO BID × 5-7 days** (cystitis only, NOT pyelonephritis)

***E. faecium* OR VRE:**
- **Linezolid 600mg PO BID × 7 days**
- **Daptomycin 6 mg/kg IV daily × 7 days**
- **Nitrofurantoin** (if cystitis only)

**Bacteremia (Without Endocarditis):**

***E. faecalis* (Ampicillin-Susceptible):**
- **Ampicillin 2g IV q4h × 7-14 days**

***E. faecium* OR Ampicillin-Resistant:**
- **Vancomycin 15-20 mg/kg IV q8-12h × 7-14 days** (if vancomycin-susceptible)

**VRE Bacteremia:**
- **Daptomycin 6-8 mg/kg IV daily × 7-14 days** (first-line)
- **Linezolid 600mg IV/PO BID × 7-14 days** (alternative, bacteriostatic)
- **Alternatives:**
  - Tigecycline 100mg IV × 1 → 50mg IV q12h
  - Quinupristin-dalfopristin 7.5 mg/kg IV q8h (*E. faecium* only, NOT *E. faecalis*)

**Endocarditis:**

***E. faecalis* (Ampicillin-Susceptible, Gentamicin-Susceptible):**
- **Ampicillin 2g IV q4h** + **gentamicin 1 mg/kg IV q8h** (or 3 mg/kg daily) × 4-6 weeks
  - **Synergy required** (neither alone is bactericidal)
  - **Monitor gentamicin levels** (goal trough <1 mcg/mL, peak 3-4 mcg/mL if q8h dosing)
  - **Gentamicin typically × 2 weeks**, then ampicillin alone × remaining 2-4 weeks (if renal function declining)

***E. faecalis* (HLAR - High-Level Aminoglycoside Resistance):**
- **Ampicillin 2g IV q4h** + **ceftriaxone 2g IV q12h × 6 weeks** (synergy, dual β-lactam)

**VRE Endocarditis:**
- **Daptomycin 8-10 mg/kg IV daily** + **ampicillin 2g IV q4h** × 6 weeks (if ampicillin MIC ≤64)
- **Consider adding gentamicin** if no HLAR
- **Consult ID specialist** (difficult to treat, high relapse rate)

**Intra-Abdominal/Pelvic Infections:**
- **Do NOT routinely add enterococcal coverage** (polymicrobial, uncertain pathogenic role)
- **Treat if:** Septic, immunocompromised, persistent despite appropriate Gram-negative/anaerobic coverage

### **Special Considerations:**

**VRE Colonization vs Infection:**
- **Colonization common** (GI tract, healthcare settings)
- **Do NOT treat colonization** (no benefit)
- **Contact precautions** (prevent transmission)

**Endocarditis:**
- **Always requires synergy** (cell-wall agent + aminoglycoside OR dual β-lactam)
- **Monotherapy inadequate** (enterococci are "tolerant" - inhibited but not killed)

**Synergy Testing:**
- **Screen for HLAR** (if HLAR, cannot use aminoglycoside for synergy)

**Duration:**
- **UTI:** 7 days (uncomplicated)
- **Bacteremia:** 7-14 days
- **Endocarditis:** 4-6 weeks

### **Infection Control (VRE):**

**Contact Precautions:**
- **Gown, gloves** for all patient contact
- **Private room** (or cohort with other VRE patients)
- **Dedicated equipment**

**Screening:**
- **Rectal swab** (detect colonization)
- **High-risk units:** ICU, oncology, transplant

**Decolonization:**
- **NOT effective** (GI colonization difficult to eradicate)

## Key Points

### **Ampicillin if *E. faecalis* (Usually Susceptible):**
- **Ampicillin 2g IV q4h** (bacteremia, endocarditis)
- **Ampicillin 500mg PO QID** (UTI)

### **VRE = Daptomycin or Linezolid:**
- **Daptomycin 6-8 mg/kg IV daily** (bacteremia, first-line)
- **Linezolid 600mg BID** (alternative, bacteriostatic)

### **Endocarditis = Synergy Required:**
- **Ampicillin + gentamicin** × 4-6 weeks
- **If HLAR:** Ampicillin + ceftriaxone (dual β-lactam)

### **Cephalosporins Do NOT Cover *Enterococcus*:**
- **Intrinsic resistance** (all generations)

### ***E. faecium* More Resistant:**
- **Often ampicillin-resistant, VRE**
- **Healthcare-associated**

### **Clinical Pearls:**
- **Ampicillin if *E. faecalis*** (usually susceptible)
- **VRE:** Daptomycin 6-8 mg/kg daily OR linezolid 600mg BID
- **Endocarditis:** Ampicillin + gentamicin (synergy required)
- **Cephalosporins do NOT cover** *Enterococcus* (intrinsic resistance)
- ***E. faecium*:** More resistant (VRE, ampicillin-resistant)
- **Do NOT treat colonization** (only infection)

## Sources

- [IDSA: VRE Guidelines 2024]
- [CID: Enterococcal Endocarditis 2024]

## Media

N/A
